Steven Cohen’s Amphastar Pharmaceuticals AMPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.11M Buy
+54,964
New +$1.11M ﹤0.01% 2771
2025
Q1
Sell
-9,200
Closed -$342K 2010
2024
Q4
$342K Sell
9,200
-29,617
-76% -$1.35M ﹤0.01% 1759
2024
Q3
$1.88M Sell
38,817
-197,019
-84% -$8.65M ﹤0.01% 1215
2024
Q2
$9.43M Sell
235,836
-26,564
-10% -$1.1M 0.02% 638
2024
Q1
$11.5M Buy
+262,400
New +$13.6M 0.03% 665
2023
Q4
Sell
-1,283
Closed -$59K 2128
2023
Q3
$59K Buy
+1,283
New +$70K ﹤0.01% 2089
2023
Q2
Sell
-65,418
Closed -$2.45M 2140
2023
Q1
$2.45M Buy
+65,418
New +$2.14M 0.01% 939
2019
Q3
Sell
-162,286
Closed -$3.43M 1118
2019
Q2
$3.43M Buy
+162,286
New +$3.39M 0.02% 582
2018
Q2
Sell
-65,000
Closed -$1.22M 960
2018
Q1
$1.22M Sell
65,000
-29,820
-31% -$561K 0.01% 800
2017
Q4
$1.82M Buy
+94,820
New +$1.77M 0.01% 752
2017
Q3
Sell
-175,000
Closed -$3.13M 863
2017
Q2
$3.13M Buy
+175,000
New +$2.78M 0.02% 573

Other funds holding AMPH

Steven Cohen's AMPH Position: Q2 2026 in Review

Steven Cohen opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2026: 54,964 shares worth $1.11M. The stake represents ﹤0.01% of the portfolio and ranks #2771 among its holdings. This is a return to the name: Steven Cohen previously reported a position in AMPH as recently as Q4 2024.

Steven Cohen first reported a position in AMPH in Q2 2017 and has held it in 11 quarters since. The position peaked at $11.5M in Q1 2024. 209 funds tracked by Wall St. Rank hold AMPH as of Q2 2026.

  • Steven Cohen held 54,964 shares of Amphastar Pharmaceuticals worth $1.11M as of Q2 2026.
  • Amphastar Pharmaceuticals was a new Steven Cohen position in Q2 2026.
  • Amphastar Pharmaceuticals made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2771 holding.
  • Steven Cohen first reported a position in Amphastar Pharmaceuticals in Q2 2017 and has held it in 11 quarters since.
  • Steven Cohen's Amphastar Pharmaceuticals position peaked at $11.5M in Q1 2024.
  • 209 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.